Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1567

1.

Host-directed kinase inhibitors act as novel therapies against intracellular Staphylococcus aureus.

Bravo-Santano N, Stölting H, Cooper F, Bileckaja N, Majstorovic A, Ihle N, Mateos LM, Calle Y, Behrends V, Letek M.

Sci Rep. 2019 Mar 19;9(1):4876. doi: 10.1038/s41598-019-41260-8.

PMID:
30890742
2.

Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).

Feng Y, Duan W, Cu X, Liang C, Minhang X.

Expert Opin Ther Pat. 2019 Mar 19. doi: 10.1080/13543776.2019.1594777. [Epub ahead of print]

PMID:
30888232
3.

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.

Li X, Shi B, Teng Y, Cheng Y, Yang H, Li J, Wang L, He S, You Q, Xiang H.

Medchemcomm. 2019 Jan 16;10(2):294-299. doi: 10.1039/c8md00413g. eCollection 2019 Feb 1.

PMID:
30881616
4.

Management of adverse effects/toxicity of ibrutinib.

Paydas S.

Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. Review.

PMID:
30878129
5.

Properties of FDA-approved small molecule protein kinase inhibitors.

Roskoski R.

Pharmacol Res. 2019 Mar 12. pii: S1043-6618(19)30425-6. doi: 10.1016/j.phrs.2019.03.006. [Epub ahead of print] Review.

PMID:
30877063
6.

Changes in immunosuppressive treatment of chronic graft-versus-host disease - comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Mar 12. pii: S1083-8791(19)30154-5. doi: 10.1016/j.bbmt.2019.03.003. [Epub ahead of print]

PMID:
30876928
7.

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib.

Nyga R, Simon L, Chouaki T, Delette C, Bennis Y, Joseph C, Marolleau JP, Slama M, Zogheib E, Maizel J.

Crit Care. 2019 Mar 12;23(1):88. doi: 10.1186/s13054-019-2385-x. No abstract available.

8.

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.

Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.

Mol Cancer Res. 2019 Mar 12. pii: molcanres.0256.2018. doi: 10.1158/1541-7786.MCR-18-0256. [Epub ahead of print]

PMID:
30862686
9.

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Cuneo A, Foà R.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019024. doi: 10.4084/MJHID.2019.024. eCollection 2019.

10.

Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.

Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, Rao Y.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0440-x. [Epub ahead of print] No abstract available.

PMID:
30858551
11.

Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.

Ran F, Liu Y, Zhang D, Liu M, Zhao G.

Bioorg Med Chem Lett. 2019 Mar 5. pii: S0960-894X(19)30131-3. doi: 10.1016/j.bmcl.2019.03.005. [Epub ahead of print]

PMID:
30857748
12.

The Treatment of Chronic Lymphatic Leukemia.

Tresckow JV, Eichhorst B, Bahlo J, Hallek M.

Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46. doi: 10.3238/arztebl.2019.0041.

13.

Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Spaner DE, McCaw L, Wang G, Tsui H, Shi Y.

Cancer Med. 2019 Mar 7. doi: 10.1002/cam4.2042. [Epub ahead of print]

14.

Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.

Naydenov AV, Taylor LP.

Oncologist. 2019 Mar 6. pii: theoncologist.2018-0619. doi: 10.1634/theoncologist.2018-0619. [Epub ahead of print]

PMID:
30842245
15.

Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 Mar 6. pii: blood-2018-08-870238. doi: 10.1182/blood-2018-08-870238. [Epub ahead of print]

PMID:
30842083
16.

Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.

Giovanni B, Ibatici A, Sola S, Brunasso AMG, Massone C.

Am J Dermatopathol. 2019 Feb 27. doi: 10.1097/DAD.0000000000001391. [Epub ahead of print] No abstract available.

PMID:
30839345
17.

Regioselective Synthesis of Highly Functionalized Pyrazoles from N-Tosylhydrazones.

Zhang Q, Tang M.

Org Lett. 2019 Mar 15;21(6):1917-1920. doi: 10.1021/acs.orglett.9b00561. Epub 2019 Mar 4.

PMID:
30829036
18.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Harrington BK, Wheeler E, Hornbuckle K, Y Shana'ah A, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L.

Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231. [Epub ahead of print]

PMID:
30821551
19.

A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.

D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Dal Bo M, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R.

Haematologica. 2019 Feb 28. pii: haematol.2018.212811. doi: 10.3324/haematol.2018.212811. [Epub ahead of print]

20.

Differences and similarities in ibrutinib and acalabrutinib effects on platelet functions.

Series J, Garcia C, Levade M, Viaud J, Sié P, Ysebaert L, Payrastre B.

Haematologica. 2019 Feb 28. pii: haematol.2018.207183. doi: 10.3324/haematol.2018.207183. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center